Home > Journals > Minerva Pediatrica > Past Issues > Minerva Pediatrica 2012 June;64(3) > Minerva Pediatrica 2012 June;64(3):307-12





A Journal on Pediatrics, Neonatology, Adolescent Medicine,
Child and Adolescent Psychiatry

Indexed/Abstracted in: CAB, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,532




Minerva Pediatrica 2012 June;64(3):307-12

language: English

Brain natriuretic peptide as a cardiotoxicity biomarker in children with hematological malignancies

Tragiannidis A. 1, Dokos C. 1, Tsotoulidou V. 1, Giannopoulos A. 1, Pana Z.-D. 1, Papageorgiou T. 1, Karamouzis M. 2, Athanassiadou F. 1

1 Second Pediatric Department, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece;
2 Laboratory of Clinical Chemistry, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece


AIM Aim of our study was to evaluate BNP as early cardiotoxicity biomarker after completion of chemotherapy in twenty children with hematological malignancies at diagnosis (t=0) and after completion of intensive chemotherapy (t=1).
METHODS: Demographic data, underlying disease, cumulative anthracyclines dose, measurement of serum BNP and evaluation of systolic function of left ventricle with ejection fraction (EF) and shortening fraction (FS) in both times . Pathological values for EF and FS were found in 4 (20%) and 1 (5%) patient at t=1, while respective values were normal at diagnosis.
RESULTS: Mean BNP values at t=0 were 59.09±19.95 pg/mL and differ significantly from values at t=1 (153.22±29.14 pg/mL) (P=0.04). Mean value of EF also differed significantly (75.42±4.11% vs. 69.87±10.51%, P=0.04). No statistic difference was found regarding FS values at both (P=0.102).
CONCLUSION: Present data indicate that anthracyclines related cardiotoxicity is registered in children with hematological malignancies and BNP represents a useful biomarker of myocardial dysfunction.

top of page

Publication History

Cite this article as

Corresponding author e-mail